Abiopharma

🔍 Schikan Johannes Gerardus Christiaan Petrus (Executive)

Company: Pharvaris N.V. (PHVS)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Sold 3,830 shares of Common Stock at $30.0692 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: false | shares_owned_after: 384,237.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 28,400 shares of Common Stock at $30.3024 per share (Direct)
  Date: 2026-04-30 | Code: S | equity_swap_involved: false | shares_owned_after: 355,837.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 670 shares of Common Stock at $31.0321 per share (Direct)
  Date: 2026-04-30 | Code: S | equity_swap_involved: false | shares_owned_after: 355,167.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: This is a scheduled sale from 10b5-1 trading plan.
• F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F3: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F4: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $31.03 to $31.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.